Skip to main content

The Clinical Haematology Department at the Jules Bordet Institute specialises in determining and treating malignant haemopathies (blood cancers). 
The Jules Bordet Institute is committed to treating these diseases with the aim of providing the patient with individualised care of the highest quality in terms of treatment and support.

In addition to treating malignant haemopathies, the Institute is also engaged in treating adolescents and young adults (AYAs) and  rare haematological cancers while developing innovative and complex techniques and therapies, including   cell therapies.

The Institute’s mission covers 3 main university fields: clinical, research and teaching. Multidisciplinarity, in both its diagnostic and therapeutic approaches, forms an inherent part of all decisions concerning the patient.  

Research projects

Some examples of clinical and translational research
 

Project 1

Protocoles de recherche clinique académiques et pharmaceutiques
  • Project leaders : Drs M. Maerevoet and N. Meuleman
  • Funding : Fonds Ariane, Pharma

Project 2

Interculturality and Transplantation  
  • Project leaders : Sandra Michiels, Patrick Crombez
  • Collaboration : MASCC (International, Prof Klastersky)
  • Funding : «Association Jules Bordet» / BHS / Fondation Kisane

Project 3

Role of radio-immunotherapy in myeloma

Project 4

ÉVALUATION DES TROUBLES COGNITIFS LIÉS AU CANCER PAR DES TESTS NEUROPSYCHOLOGIQUES ET DES TECHNIQUES D’IMAGERIE FONCTIONNELLES CHEZ LES ADOLESCENTS ET JEUNES ADULTES (AJA) ATTEINTS DE LYMPHOMES
  • Project leader : Alice Wolfromm

Our team

  • Hematologists
    • Pr Nathalie MEULEMAN, Head of Department
    • Pr Virginie DE WILDE, Head of Department (associated)
    • Dr Fabio ANDREOZZI
    • Dr Elisa BRAUNS
    • Dr Sarah BUNTINX
    • Dr Martin COLARD
    • Dr Julie DALLEMAGNE
    • Pr Philippe LEWALLE
    • Dr Marie MAEREVOET
    • Dr Hanne MASSA
    • Dr Fulvio MASSARO
    • Dr Ornella RIZZO
    • Dr Adriano SALAROLI
    • Dr Chloé SPILLEBOUDT
    • Dr Aude THEUNISSEN
    • Dr Alexandra VAN UYTVANCK 
    • Dr Marie VERCRUYSSEN
    • Pr Sebastian WITTNEBEL
    • Dr Alice WOLFROMM
       
  • Consultants
    • Dr Marine DE VICQ
    • Dr Françoise LE MOINE
    • Pr Serge MOTTE
    • Pr Béatrice GULBIS

THE TEAM

12/05/2025

 Scientific publications

Linking clinical and population-based data in older patients with cancer in Belgium: Feasibility and clinical outcomes.

Authors : Depoorter V, Vanschoenbeek K, Decoster L, De Schutter H, Debruyne PR, De Groof I, Bron D, Cornélis F, Luce S, Focan C, Verschaeve V, Debugne G, Langenaeken C, Van den Bulck H, Goeminne JC, Teurfs W, Jerusalem G, Schrijvers D, Petit B, Rasschaert M, Praet JP, Vandenborre K, Milisen K, Flamaing J, Kenis C, Verdoodt F, Wildiers H
Year : 2023
Journal : J Geriatr Oncol
Pages : 101428

Potential of Mesenchymal Stromal Cell-Derived Extracellular Vesicles as Natural Nanocarriers: Concise Review.

Authors : Draguet F, Bouland C, Dubois N, Bron D, Meuleman N, Stamatopoulos B, Lagneaux L
Year : 2023
Journal : Pharmaceutics
Volume : 15

Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer.

Authors : Loi S, Salgado R, Adams S, Pruneri G, Francis PA, Lacroix-Triki M, Joensuu H, Dieci MV, Badve S, Demaria S, Gray R, Munzone E, Drubay D, Lemonnier J, Sotiriou C, Kellokumpu-Lehtinen PL, Vingiani A, Gray K, André F, Denkert C, Piccart-Gebhart M, Roblin E, Michiels S
Year : 2022
Journal : NPJ Breast Cancer
Volume : 8
Pages : 3

Polypoid colon mucosa in a leukemia patient.

Authors : Lifrange F, Van Gossum A, Verset L, Bron D, Gomez-Galdon M, Demetter P
Year : 2022
Journal : Acta Gastroenterol Belg
Volume : 85
Pages : 118-119

Brentuximab Vedotin and Pembrolizumab Combination in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Single-Centre Retrospective Analysis.

Authors : Massaro F, Meuleman N, Bron D, Vercruyssen M, Maerevoet M
Year : 2022
Journal : Cancers (Basel)
Volume : 14